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• Brain metastases are the most common 
intracranial malignancy, occurring in 9% to 17% 
of patients with cancer1
• Treatments include surgical resection, whole-
brain radiotherapy (WBRT) and stereotactic 
radiosurgery (SRS)
• SRS has become the more popular option 
because of its relatively short, convenient, and 
noninvasive treatment course2
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• Review of treatment for cases presenting with 
limited brain metastases between 2014-2016 
• Determine if treatment at LVHN was in 
accordance with 2018 NCCN Guidelines3
• Determine overall survival for patients with 
limited brain metastases by treatment type
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METHODS
Figure 1 (above). Distribution by type of brain metastases: 
50.00% had limited, 44.33% had extensive, 5.66% was not 
determined. 
Patients with limited brain metastases: 65.09% underwent 




























* 7 of 34 with 
systemic disease 
are alive (20.59% 
survival). 
* 17 of 35 with-
out systemic 




• Treatment for limited brain metastases at 
LVHN followed 2018 NCCN Guidelines3
• Survival was higher for patients who 
received SRS 
• Eliminating systemic disease increased 
survival for limited brain metastases 
treated with SRS 
• Future studies are needed to evaluate the 
efficacy of SRS in limited brain 
metastases of different cancer types
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